Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer

REFERENCES

• Mahmood K, Naeem M, Rahimnajjad NA. Metformin: the hidden chronicles of a magic drug. Eur J Int Med 2013;24(1):20–26.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000;284(4):472–477.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138(3):269–274.
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254–258.
   PubMed Web of Science ®Google Scholar
• Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res Treat 2013;137(3):807–816.
   PubMed Web of Science ®Google Scholar
• Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo. AM Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27(20):3297–3302.
   PubMed Web of Science ®Google Scholar
• Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009;8(13):2031–2040.
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase—Dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269–10273.
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Nat Acad Sci USA 2013;110(3):972–977.
   PubMed Web of Science ®Google Scholar
• Jung J-W, Park S-B, Lee S-J, Seo M-S, Trosko JE, Kang K-S. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS ONE 2011;6(11):e28068. PMID: 22132214.
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69(19):7507–7511.
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108(8):1167–1174.
   PubMed Web of Science ®Google Scholar
• Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, DeCensi A. Dual effect of Metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012;30(21):2593–2600.
   PubMed Web of Science ®Google Scholar
• Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar J, Thompson A. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011;128(3):783–794.
   PubMed Web of Science ®Google Scholar
• Niraula S, Dowling RO, Ennis M, Chang M, Done S, Hood N, Escallon J, Leong W, McCready D, Reedijk M, Stambolic V, Goodwin P. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012;135(3):821–830.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11(2 Pt 2):951s–958s.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99(2):167–170.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists. J Clin Oncol 2005;23(11):2477–2492.
   PubMed Web of Science ®Google Scholar
• Dowsett M. Optimizing the implementation of future treatment using surrogate end-points. Breast Cancer Res 2008;10(Suppl. 4):S26. PMCID: PMC2614852.
   PubMedGoogle Scholar
• DeCensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, Pruneri G, Viale G, Bonanni B. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol 2011;22(3):582–587.
   PubMed Web of Science ®Google Scholar
• Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol 2010;28(16):2784–2795.
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Wolff AC. Clinical notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol 2011;29(15):e458. PMID: 21502545.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Nat Cancer Inst 2011;103(22):1656–1664.
   PubMed Web of Science ®Google Scholar
• Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5(10):2512–2521.
   PubMed Web of Science ®Google Scholar
• Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68(15):6084–6091.
   PubMed Web of Science ®Google Scholar
• Vaccaro O, Masulli M, Cuomo V, Rivellese AA, Uusitupa M, Vessby B, Hermansen K, Tapsell L, Riccardi G. Comparative evaluation of simple indices of insulin resistance. Metabolism 2004;53(12):1522–1526.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412–419.
   PubMed Web of Science ®Google Scholar
• Ooi S, Martinez M, Li C. Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat 2011;127(3):729–738.
   PubMed Web of Science ®Google Scholar
• Wang Y, Beydoun MA. The obesity epidemic in the United States—gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev 2007;29(1):6–28.
   PubMed Web of Science ®Google Scholar
• Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 2006;29(6):1263–1268.
   PubMed Web of Science ®Google Scholar
• TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F. A clinical trial to maintain glycemic control in youth with type 2 diabetes. New Eng J Med 2012;366(24):2247–2256.
   PubMed Web of Science ®Google Scholar
• Kim C, Golden SH, Mather KJ, Laughlin GA, Kong S, Nan B, Barrett-Connor E, Randolph JF. Racial/ethnic differences in Sex Hormone Levels among Postmenopausal Women in the Diabetes Prevention Program. J Clin Endocrinol Metabol 2012;97(11):4051–4060.
   PubMed Web of Science ®Google Scholar
• Hasson RE, Adam TC, Davis JN, Weigensberg MJ, Ventura EE, Lane CJ, Roberts CK, Goran MI. Ethnic differences in insulin action in obese African-American and Latino adolescents. J Clin Endocrinol Metabol 2010;95(8):4048–4051.
   PubMed Web of Science ®Google Scholar
• Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008;9(4):415–422.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Parulekar W, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V. Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer. J Clin Oncol 2013;31: (Suppl; abstr 1033).
   Google Scholar
• Farooqi IS, O'rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009;89(3):980S–984S.
   PubMed Web of Science ®Google Scholar
• Panarotto D, Ardilouze J-L, Tessier D, Maheux P. The degree of hyperinsulinemia and impaired glucose tolerance predicts plasma leptin concentrations in women only: a new exploratory paradigm. Metabolism 2000;49(8):1055–1062.
   PubMed Web of Science ®Google Scholar
• Van Rossum EF, Nicklas BJ, Dennis KE, Berman DM, Goldberg AP. Leptin responses to weight loss in postmenopausal women: relationship to sex-hormone binding globulin and visceral obesity. Obesity Res 2000;8(1):29–35.
   PubMedGoogle Scholar